Read by QxMD icon Read

Tumori | Page 4

Eliana La Rocca, Vanessa Lici, Tommaso Giandini, Francesca Bonfantini, Sarah Frasca, Michela Dispinzieri, Massimiliano Gennaro, S Serena Di Cosimo, Laura Lozza, Emanuele Pignoli, Riccardo Valdagni, Maria Carmen De Santis
PURPOSE: To examine interobserver variability between the radiation oncologist (RTO) and the radiation therapist (RTT) in delineating the tumor bed (TB) in early breast cancer (BC). METHODS: We retrospectively analyzed patients who received a radiotherapy boost to the TB. In a first group, the clinical target volume (CTV) for the boost was the surgical bed, defined by using surgical clips. In a second group, the CTV was defined by identifying a seroma cavity or a metallic find on the scar...
March 27, 2019: Tumori
Federica Grosso, Alessandro Croce, Roberta Libener, Narciso Mariani, Massimo Pastormerlo, Antonio Maconi, Caterina Rinaudo
PURPOSE: To assess whether asbestos fibers may be observed in liver tissue of patients with cholangiocarcinoma (CC) with environmental or working asbestos exposure. METHODS: Detection of fibers was performed directly on histologic sections of liver from 7 patients with CC using optical microscope and variable pressure scanning electron microscopy equipped with energy-dispersive spectroscopy (VP-SEM/EDS). All patients were from Casale Monferrato, Italy, a highly asbestos-polluted town...
March 27, 2019: Tumori
Lorenzo Livi, Beatrice Detti, Giulio Francolini, Francesca Terziani, Luca Triggiani, Rolando M D'Angelillo, Gianluca Ingrosso
Prostate cancer is the second most frequent cancer worldwide, with a very high rate of progression despite treatment. The most aggressive form of the disease is known as castration-resistant prostate cancer, which carries a poor prognosis. We reviewed available literature regarding the combination of abiraterone acetate antihormonal drug and ablative radiation therapy for the treatment of metastatic castration-resistant prostate cancer. This dual treatment may enhance the effects of second-line hormonal therapy, as radiotherapy renders cancer cells more prone to immune-mediated cytotoxicity...
March 25, 2019: Tumori
Byoung Soo Kwon, Ji Hyun Park, Seulgi Kim, Sojung Park, Wonjun Ji, Woo Sung Kim, Jae Cheol Lee, Yu Rang Park, Chang-Min Choi
BACKGROUND: This study aimed to estimate therapeutic effects of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in real-world practice, by analyzing survival outcomes in an unselected, Korean female population with advanced lung cancer based on the National Health Insurance Service database. METHODS: We identified women with newly diagnosed advanced lung cancer from January 2004 to December 2013. For progression-free survival (PFS) and overall survival (OS) analyses, patients were defined into the following subgroups: group A, treated with first-generation EGFR-TKI ⩾6 months; group B, treated with EGFR-TKIs <6 months but at least >1 month; and group C, treated with cytotoxic chemotherapy as follows: monotherapy or combination therapy with gemcitabine or pemetrexed; or monotherapy with docetaxel, paclitaxel, or vinorelbine...
March 25, 2019: Tumori
Laura Botta, Gemma Gatta, Annalisa Trama, Riccardo Capocaccia
BACKGROUND: The proportion of patients cured of cancer is usually estimated with cure models assuming they have the same death risk as the general population. These patients, even when cured, often maintain an extra death risk compared to the overall population. Our aims were to estimate this extra risk, and to take it into account in estimating cure proportions and relative survival (RS). METHODS: We used RS mixture model with an additional parameter expressing the extra noncancer death risk of patients, assumed constant with age...
March 25, 2019: Tumori
Juan A Muñoz-Largacha, Sowmya R Rao, Laurence H Brinckerhoff, Benedict D Daly, Hiran C Fernando, Virginia R Litle, Kei Suzuki
OBJECTIVE: To determine if induction chemotherapy with concurrent high-dose radiation followed by resection is associated with improved survival in patients with nonsuperior sulcus lung cancer with chest wall invasion. METHODS: We performed a retrospective review of clinical T3 (chest wall invasion) N0/N1 patients with non-small cell lung cancer who underwent surgical resection between January 1, 1992, and January 31, 2017. Exclusion criteria included superior sulcus tumors and resection performed for palliation/recurrence...
March 25, 2019: Tumori
Roberto Lisi, Gessica Abate, Pasqualina D'Urso, Maria Teresa Martinetti, Benedetta Siniscalchi, Francesco Marampon, Nadia Bulzonetti, Vincenzo Tombolini
BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is a rare benign cancer that can express a more aggressive phenotype related to the genetic mutation of the anaplastic lymphoma kinase receptor (ALK). Involvement of trachea is extremely rare and due to the clinical and radiologic nonspecificity, the definitive diagnosis is based on the histologic evaluation of tissue specimens. Total surgical excision is curative and chemotherapy or radiotherapy has been employed in the treatment of unresectable tumors or as adjuvant therapies...
March 22, 2019: Tumori
Giuseppe Boni, Fabio Monari
No abstract text is available yet for this article.
March 14, 2019: Tumori
Sara Lonardi, Guglielmo Nasti, Daniele Fagnani, Donatello Gemma, Libero Ciuffreda, Cristina Granetto, Sara Lucchesi, Alberto Ballestrero, Maria Biglietto, Ilaria Proserpio, Francesca Bergamo, Emanuela Proietti, Giuseppe Tonini
AIMS: BEAWARE investigated the pattern of first-line bevacizumab early interruption in the Italian real-world setting of metastatic colorectal cancer. METHODS: A total of 386 patients were followed for 15 months after first-line chemotherapy + bevacizumab start. The rate of bevacizumab interruption for progression or adverse drug reactions (ADRs) constituted the primary endpoint. RESULTS: A total of 78.2% of patients interrupted bevacizumab: 56...
March 11, 2019: Tumori
Laurien De Roeck, Sandra Nuyts
INTRODUCTION: The most important long-term effect of radiotherapy is induction of secondary cancers. A rare radiation-induced tumor is a squamous cell carcinoma of the external auditory canal. Case reports have been described in Asian patients after radiotherapy for nasopharyngeal cancer. CASE DESCRIPTION: We describe an unusual case report of a 53-year-old Caucasian man who developed squamous cell carcinomas of the right and left external auditory canal, respectively 29 and 30 years after radiotherapy for a pituitary adenoma...
February 26, 2019: Tumori
Michele Fiore, Pasquale Trecca, Giuseppe Perrone, Michelina Amato, Daniela Righi, Lucio Trodella, Rolando M D'Angelillo, Sara Ramella
INTRODUCTION: Targeted therapies against epidermal growth factor receptor (EGFR) have revolutionized the treatment of a subset of lung adenocarcinomas that have EGFR-activating mutations; however, all patients treated with EGFR tyrosine kinase inhibitors (TKIs) ultimately develop resistance. Histologic transformation of EGFR-mutant adenocarcinoma to small cell lung cancer (SCLC) is a resistance mechanism rarely reported in the literature. CASE PRESENTATION: We describe the case of a woman with metastatic lung cancer adenocarcinoma with mutated EGFR with an initial response to gefitinib and radiation therapy, who progressed after 18 months due to the development of a resistance mechanism...
February 24, 2019: Tumori
Antonio Mastroianni, Rossella Panella, Daniele Morelli
PURPOSE: The integration of expertise between oncologist and clinical biochemist for the monitoring and diagnosis of plasma cell dyscrasia is crucial. In some cases, medical laboratory scientists can provide an original contribution using the appropriate techniques to arrive at a diagnosis. METHODS: We report a case of 67-year-old woman who was admitted to our hospital for bone pain. Imaging studies showed multiple diffuse bone lytic lesions, and a laboratory screen revealed anemia and altered creatinemia; serum capillary zone electrophoresis confirmed a monoclonal peak in the γ-zone that had been known since 2011, typed as immunoglobulin G kappa by immunosubtraction electrophoresis...
February 24, 2019: Tumori
Tchin Darré, Brahima Doukouré, Mohamed Kouyaté, Toukilnan Djiwa, Doh Kwamé, Gado Napo-Koura
BACKGROUND: Primary carcinoid tumors are rare and constitute 0.23% of all testicular tumors. We report a case of primary carcinoid tumor of testicular localization, with a review of the literature. CASE PRESENTATION: A 29-year-old man, without specific ascendants, consulted the urology department for progressive scrotal swelling of 6 months, associated with pain. After surgery, histology showed diffuse tumor proliferation composed of small round monotone cells with hyperchromatic nuclei evoking undifferentiated carcinoma...
February 24, 2019: Tumori
Concetta Laliscia, Angiolo Gadducci, Maria Grazia Fabrini, Amelia Barcellini, Emanuela Parietti, Francesco Pasqualetti, Riccardo Morganti, Valentina Mazzotti, Ines Cafaro, Fabiola Paiar
OBJECTIVE: To assess the clinical outcome of patients treated with radiotherapy (RT) for recurrent squamous cell carcinoma of the vulva after primary surgery. METHODS: Fifty-six patients developed recurrent disease after surgery, consisting of deep total vulvectomy with inguino-femoral lymphadenectomy in 44 (78.6%) and deep partial vulvectomy with inguino-femoral lymphadenectomy in 12 (21.4%). All patients underwent RT at the Divisions of Radiotherapy, University of Pisa and ASST Cremona, between 1992 and 2016...
February 21, 2019: Tumori
Marco Siano, Salvatore Alfieri, Roberta Granata, Giuseppina Calareso, Ester Orlandi, Cristiana Bergamini, Laura Deborah Locati
PURPOSE: Two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, have been approved for recurrent/metastatic (R/M) medullary thyroid carcinoma (MTC). To date, it is still debated when and which TKI has to be started in R/M MTC patients. This is due to 1) TKI-related toxicity burden, 2) no overall survival benefit for either TKI, and 3) progression-free survival improvement in MTC subgroups ( RETM918T and RAS mutations) treated with cabozantinib. Herein, we present a case of R/M MTC with a discordant disease behavior because of spontaneous regression of some parenchymal sites along with progression of bone metastases, putting into the question the best timing for starting TKIs in R/M MTC...
February 19, 2019: Tumori
(no author information available yet)
No abstract text is available yet for this article.
February 2019: Tumori
Pauline Roux, Sophie Knight, Monique Cohen, Jean Marc Classe, Chafika Mazouni, Marie-Pierre Chauvet, Fabien Reyal, Pierre-Emmanuel Colombo, Eva Jouve, Nicolas Chopin, Emile Daraï, Charles Coutant, Eric Lambaudie, Gilles Houvenaeghel
OBJECTIVES: To analyze axillary lymph node involvement (ALNI) rate and survival for mucinous (MC) and tubular (TC) breast carcinomas considered being of very good prognosis and for which an axillary surgical exploration could be questioned. METHODS: Our multicentric cohort consisted of 21,135 patients with clinically node-negative invasive breast cancer, without neoadjuvant therapy, between 1999 and 2013 in 10 French centers. ALNI rate and survival were analyzed according to patient and tumor characteristics...
February 2019: Tumori
Giorgio Bogani, Antonino Ditto, Umberto Leone Roberti Maggiore, Cono Scaffa, Lavinia Mosca, Valentina Chiappa, Fabio Martinelli, Domenica Lorusso, Francesco Raspagliesi
OBJECTIVE: To test the safety and effectiveness of neoadjuvant chemotherapy followed by interval debulking surgery in unresectable stage IVB serous endometrial cancer. METHODS: Data of consecutive stage IVB serous endometrial cancer are reviewed. Patients undergoing neoadjuvant chemotherapy plus interval debulking surgery were propensity matched with patients undergoing primary surgery followed by adjuvant treatment. RESULTS: Thirty-four patients were diagnosed with a stage IVB endometrial cancer...
February 2019: Tumori
Maria Teresa Bustamante-Teixeira, Maria do Rosário D O Latorre, Maximiliano R Guerra, Luana F Tanaka, Laura Botta, Annalisa Trama, Gemma Gatta
INTRODUCTION: Rare cancers are a challenge for clinical practice as well as for epidemiology and public health. Studies on this subject are few and limited to the study of cases with scarce epidemiologic information. This study aimed to evaluate the incidence of rare cancers and to compare the demographic, anatomic, and histologic characteristics of rare and nonrare (common) cancers. METHODS: Incidence data were obtained from the Population-based Cancer Registry of São Paulo, Brazil...
January 30, 2019: Tumori
Jian-Jun Lu, Yao-Wu Su, Chao-Jun Wang, Di-Feng Li, Liang Zhou
The present study aimed to investigate the role of semaphorin 4D (Sema4D) in bladder cancer cell proliferation and metastasis in vivo and in vitro. Effects of Sema4D modulation on cancer cell viability and clonogenic abilities were assessed by MTT assay and colony formation assay. Cell apoptosis, cell cycle analysis, transwell assays, and wound-healing assays were also assayed. A mouse model of bladder cancer was established to observe the tumorigenesis in vivo. Our data showed that Sema4D was 4-fold upregulated in clinical bladder cancer tissues relative to noncancerous ones and differentially expressed in bladder cancer cell lines...
January 24, 2019: Tumori
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"